Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation

Genes & Development
Nilotpal RoyMatthias Hebrok

Abstract

Pancreatic ductal adenocarcinoma (PDA) develops predominantly through pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) precursor lesions. Pancreatic acinar cells are reprogrammed to a "ductal-like" state during PanIN-PDA formation. Here, we demonstrate a parallel mechanism operative in mature duct cells during which functional cells undergo "ductal retrogression" to form IPMN-PDA. We further identify critical antagonistic roles for Brahma-related gene 1 (Brg1), a catalytic subunit of the SWI/SNF complexes, during IPMN-PDA development. In mature duct cells, Brg1 inhibits the dedifferentiation that precedes neoplastic transformation, thus attenuating tumor initiation. In contrast, Brg1 promotes tumorigenesis in full-blown PDA by supporting a mesenchymal-like transcriptional landscape. We further show that JQ1, a drug that is currently being tested in clinical trials for hematological malignancies, impairs PDA tumorigenesis by both mimicking some and inhibiting other Brg1-mediated functions. In summary, our study demonstrates the context-dependent roles of Brg1 and points to potential therapeutic treatment options based on epigenetic regulation in PDA.

References

Jan 1, 1992·Virchows Archiv. B, Cell Pathology Including Molecular Pathology·H P ElsässerH F Kern
May 17, 2006·Genes & Development·Aram F HezelRonald A Depinho
Jun 27, 2007·The American Journal of Pathology·Liqin ZhuStephen F Konieczny
Oct 26, 2007·Nature·Claude GazinMichael R Green
Feb 28, 2008·Nuclear Receptor Signaling·Kevin W Trotter, Trevor K Archer
Mar 15, 2008·Biochemical and Biophysical Research Communications·Hiroaki WatanabeB Mark Evers
Oct 4, 2008·The Journal of Biological Chemistry·Sylvie ThuaultAristidis Moustakas
Nov 26, 2008·Proceedings of the National Academy of Sciences of the United States of America·Nils HabbeAnirban Maitra
Nov 26, 2008·Proceedings of the National Academy of Sciences of the United States of America·Jean-Paul De La OL Charles Murtaugh
Dec 5, 2008·Proceedings of the National Academy of Sciences of the United States of America·Akari InadaSusan Bonner-Weir
Jan 16, 2009·The Journal of Biological Chemistry·Stephen FlowersElizabeth Moran
Jan 31, 2009·The American Journal of Pathology·Sugiko WatanabeMitsuyoshi Nakao
Mar 18, 2009·Bioinformatics·Cole TrapnellSteven L Salzberg
May 25, 2010·The British Journal of Dermatology·H LinG Li
Sep 4, 2010·Nature Reviews. Cancer·John P MorrisMatthias Hebrok
Sep 28, 2010·Nature·Panagis FilippakopoulosJames E Bradner
Feb 8, 2011·Applied Immunohistochemistry & Molecular Morphology : AIMM·Jason Y ParkRalph H Hruban
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Sep 6, 2011·Cell·Jake E DelmoreConstantine S Mitsiades
Dec 3, 2011·The Journal of Clinical Investigation·Maximilian Reichert, Anil K Rustgi
Jan 12, 2012·Proceedings of the National Academy of Sciences of the United States of America·A Hunter ShainJonathan R Pollack
Nov 9, 2012·Digestive Diseases and Sciences·Lang ZhaZiwei Wang
Dec 12, 2012·International Journal of Oncology·Masakatsu NumataYohei Miyagi
Jan 29, 2013·PloS One·A Hunter Shain, Jonathan R Pollack
Apr 30, 2013·Gastroenterology·Ben Z Stanger, Matthias Hebrok
Jun 22, 2013·Nature Protocols·Maximilian ReichertAnil K Rustgi
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Jan 20, 2016·Trends in Endocrinology and Metabolism : TEM·Stephanie A Campbell, Brad G Hoffman
Dec 26, 2015·Developmental Cell·Nilotpal Roy, Matthias Hebrok
Dec 19, 2015·Stem Cells International·Maximilian ReichertGuido von Figura
Oct 23, 2016·Cellular and Molecular Life Sciences : CMLS·Lidong Sun, Jia Fang
Jul 28, 2016·Drug Discovery Today·Aik-Choon TanPaul H Huang
Dec 22, 2016·International Journal of Molecular Sciences·Brittany R Silverman, Jiaqi Shi
Jan 24, 2016·Cold Spring Harbor Symposia on Quantitative Biology·Nasun HahRonald M Evans
Jan 18, 2017·Proceedings of the National Academy of Sciences of the United States of America·Mara H ShermanRonald M Evans
Jul 31, 2018·Epigenetics : Official Journal of the DNA Methylation Society·David L MarksMartin E Fernandez-Zapico
Aug 24, 2018·Genes & Development·Stephen D'AmicoNancy C Reich
Nov 30, 2018·The Journal of Clinical Investigation·Yufeng DingJun Qin
Nov 13, 2018·Annual Review of Physiology·Yaqing ZhangMarina Pasca di Magliano
Oct 28, 2019·International Journal of Molecular Sciences·Nashwa El Hadidy, Vladimir N Uversky
Mar 21, 2019·Gut·Elisabeth Hessmann, Volker Ellenrieder
Nov 5, 2017·Oncotarget·Sivan IzraelyIsaac P Witz
Jun 11, 2016·Oncotarget·Vaibhav SahaiHidayatullah G Munshi
Apr 10, 2015·Nature Reviews. Cancer·Sarah Seton-Rogers
Jul 13, 2017·Genes & Development·Stephano S MelloLaura D Attardi
Jan 13, 2019·Proceedings of the National Academy of Sciences of the United States of America·Yukiko HiramatsuHiroshi Seno
Jun 27, 2019·Journal of Clinical Medicine·Yu-Hsuan HungMei-Ren Pan
Feb 6, 2020·Cell Death & Disease·Pan WangXin Chen
Mar 6, 2017·Surgery Today·Junpei YamaguchiMasato Nagino
Jul 13, 2017·PloS One·Benedikt KaufmannDaniel Hartmann
May 25, 2020·Virchows Archiv : an International Journal of Pathology·Fumio KinoshitaYoshinao Oda
Jul 28, 2016·Current Opinion in Gastroenterology·Smrita Sinha, Steven D Leach
Sep 5, 2018·Nature Communications·Li-Yu HuangWenyi Wei
Jul 18, 2018·ELife·Geulah LivshitsScott W Lowe
Jul 17, 2018·The Journal of Clinical Investigation·Motoyuki TsudaHiroshi Seno
Apr 16, 2019·Expert Review of Anticancer Therapy·Krystal A OrlandoBernard E Weissman
Oct 20, 2020·Human Molecular Genetics·Jake J ReskeRonald L Chandler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.